Experimental malaria-associated acute respiratory distress syndrome is dependent on the parasite-host combination and coincides with normocyte invasion by Vandermosten, L. et al.
Vandermosten et al. Malar J  (2018) 17:102  
https://doi.org/10.1186/s12936-018-2251-3
RESEARCH
Experimental malaria-associated acute 
respiratory distress syndrome is dependent 
on the parasite-host combination and coincides 
with normocyte invasion
Leen Vandermosten1†, Thao‑Thy Pham1†, Hendrik Possemiers1†, Sofie Knoops1, Evelien Van Herck1, 
Julie Deckers1,2, Blandine Franke‑Fayard3, Tracey J. Lamb4, Chris J. Janse3, Ghislain Opdenakker1 
and Philippe E. Van den Steen1*
Abstract 
Background: Malaria‑associated acute respiratory distress syndrome (MA‑ARDS) is a complication of malaria with 
a lethality rate of up to 80% despite anti‑malarial treatment. It is characterized by a vast infiltration of leukocytes, 
microhaemorrhages and vasogenic oedema in the lungs. Previously, a mouse model for MA‑ARDS was developed by 
infection of C57BL/6 mice with the Edinburgh line NK65‑E of Plasmodium berghei.
Results: Here, both host and parasite factors were demonstrated to play crucial roles in the development and sever‑
ity of lung pathology. In particular, the genetic constitution of the host was an important determinant in the develop‑
ment of MA‑ARDS. Both male and female C57BL/6, but not BALB/c, mice developed MA‑ARDS when infected with 
P. berghei NK65‑E. However, the New York line of P. berghei NK65 (NK65‑NY) did not induce demonstrable MA‑ARDS, 
despite its accumulation in the lungs and fat tissue to a similar or even higher extent as P. berghei NK65‑E. These two 
commonly used lines of P. berghei differ in their red blood cell preference. P. berghei NK65‑NY showed a stronger pre‑
dilection for reticulocytes than P. berghei NK65‑E and this appeared to be associated with a lower pathogenicity in the 
lungs. The pulmonary pathology in the C57BL/6/P. berghei NK65‑E model was more pronounced than in the model 
with infection of DBA/2 mice with P. berghei strain ANKA. The transient lung pathology in DBA/2 mice infected with P. 
berghei ANKA coincided with the infection phase in which parasites mainly infected normocytes. This phase was fol‑
lowed by a less pathogenic phase in which P. berghei ANKA mainly infected reticulocytes.
Conclusions: The propensity of mice to develop MA‑ARDS during P. berghei infection depends on both host and 
parasite factors and appears to correlate with RBC preference. These data provide insights in induction of MA‑ARDS 
and may guide the choice of different mouse‑parasite combinations to study lung pathology.
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Background
Malaria is a world-wide disease with large areas of ende-
micity in sub-Saharan Africa, Asia and South America. 
Caused by infection with Plasmodium parasites, malaria 
affects around 200 million people, resulting in more than 
400,000 deaths each year [1]. Plasmodium parasites are 
transmitted through the bites of infected female Anoph-
eles mosquitos. The symptoms range from non-lethal 
uncomplicated malaria with fever, headache and vom-
iting, to life-threatening complications, such as severe 
malarial anaemia, cerebral malaria (CM), placental 
malaria and malaria-associated acute respiratory distress 
syndrome (MA-ARDS) [2]. Adults from high transmis-
sion areas are semi-immune and mostly protected against 
severe complications, including MA-ARDS. Thus, most 
cases of MA-ARDS are found in areas with low transmis-
sion of malaria and in non-immune travellers [3].
MA-ARDS has been found in patients infected with 
the two main species infecting humans, Plasmodium 
falciparum or Plasmodium vivax. MA-ARDS is also a 
main complication in Plasmodium knowlesi-infected 
patients [4], and some cases with Plasmodium ovale or 
Plasmodium malariae have been reported [5, 6]. The 
severity of MA-ARDS varies depending on the species 
of Plasmodium concerned, with the worst prognosis 
for P. falciparum infections [7, 8]. This may, in part, be 
related to distinct preferences for invading immature 
red blood cells (RBCs) or reticulocytes versus mature 
RBCs or normocytes [9, 10]. P. vivax and P. ovale 
merozoites only invade reticulocytes [11, 12]. This 
strongly reduces the number of cells available for inva-
sion, since only between 1 and 2% of the total RBCs in 
the circulation are reticulocytes in healthy individuals. 
The reticulocyte restriction generally results in lower 
parasitaemias and has been linked to lower virulence 
compared to species which also invade normocytes, 
such as P. falciparum. However, lethal P. vivax-associ-
ated ARDS cases have been described in India [13].
MA-ARDS is characterized by an excessive pulmo-
nary inflammation and breakdown of the alveolar-cap-
illary membrane, resulting in overwhelming vasogenic 
oedema, alveolar flooding and severe hypoxaemia [3]. 
Adult patients with MA-ARDS have high mortality 
rates, up to 80%, despite anti-malarial treatment. The 
precise aetiology is poorly understood. Post-mortem 
histological analyses and data from experimental MA-
ARDS models have indicated the occurrence of para-
site sequestration and apoptosis of endothelial cells 
[14–19]. Sequestration of P. falciparum-infected RBCs 
is assumed to be highly important in the pathology of 
malaria [20]. Importantly, a massive inflammatory reac-
tion occurs in the lungs during MA-ARDS [3, 15, 18], 
but the determinants which influence these phenomena 
remain poorly studied. This inflammation leads to 
accumulation of leukocytes in the pulmonary vascula-
ture. Abundant macrophages and monocytes infiltrate 
the lungs of patients with MA-ARDS, in addition to 
lymphocytes and a few neutrophils [3]. This induced 
inflammation may lead to alveolar-capillary damage 
with a fatal outcome. Malaria pigment or haemozoin 
is abundantly present in infected RBCs (iRBCs), mac-
rophages and monocytes in the lungs. The correlation 
of haemozoin deposition with pulmonary oedema and 
inflammatory cytokine induction in the lungs of mice 
with MA-ARDS suggests an important role for haemo-
zoin in the pathogenesis [17].
To investigate the pathogenesis of MA-ARDS, sev-
eral mouse models for MA-ARDS have been proposed 
in the past 10  years. Pulmonary oedema manifests in 
C57BL/6 mice infected with the Plasmodium berghei 
strain ANKA, the classical model for experimental 
cerebral malaria (ECM). This model has been used to 
investigate the pathogenesis of MA-ARDS [15, 21, 22]. 
However, the early and fulminant cerebral pathology 
in this model tends to limit the time-window avail-
able to study the pulmonary pathology. Therefore, 
several groups have developed alternative models of 
MA-ARDS. Epiphanio et  al. [23] developed a model 
based on the infection of DBA/2 mice with P. berghei 
ANKA. These mice are entirely resistant to the cerebral 
pathology and approximately 50% of the mice develop 
malaria-associated acute lung injury (MA-ALI). Hee 
et al. [24] proposed the infection of C57BL/6 mice with 
Plasmodium berghei strain K173, which also causes 
lung pathology with increased pulmonary water con-
tent, although no protein-rich alveolar oedema could 
be documented. P. berghei K173 in C57BL/6 mice has 
also been used as a model of ECM with early death after 
infection due to cerebral pathology [25]. Plasmodium 
chabaudi AS-infected C57BL/6 mice develop very little 
lung oedema [18]. However, a recent study showed that 
P. chabaudi CB, a more virulent strain than P. chabaudi 
AS, does cause lung oedema associated with pulmonary 
inflammation and cell death [26].
Previously, a model for MA-ARDS was developed 
based on the infection of C57BL/6 mice with parasites 
of the NK65 strain of P. berghei [18]. This strain of P. 
berghei does not cause ECM in C57BL/6 mice, but leads 
to lethal pulmonary inflammation with protein-rich 
interstitial and alveolar oedema. The incidence of pul-
monary pathology in this mouse model is high as more 
than 90% of infected mice develop MA-ARDS. How-
ever, infection of C57BL/6 mice with parasites of the 
NK65 strain has also been documented by other groups 
without any mention of pulmonary pathology and with 
sometimes highly different parasitaemia kinetics [27, 
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28]. Therefore, in this study it was investigated why these 
differences occur.
With mouse models of ECM, it is known that both par-
asite and host factors define the severity of disease. For 
example, parasites of the P. berghei ANKA strain induce 
ECM in C57BL/6 mice whereas cerebral complications 
are absent in BALB/c mice [29]. In rats, the age of the 
animal is an important factor in the development of cere-
bral complications with P. berghei ANKA infections [30]. 
Parasite factors also appear to play a role in ECM, since it 
has been demonstrated that various cloned lines derived 
from P. berghei ANKA induced differences in the pathol-
ogy of ECM [29]. These differences in pathology empha-
size the need for detailed data on the course of infections 
and disease in order to make a rational choice for certain 
parasite-host combinations. In contrast to ECM, less is 
known about lung disease in different mouse-parasite 
combinations.
In this study, the induction and severity of MA-ARDS 
in different mouse and parasite strains was analysed. This 
included comparisons of P. berghei NK65 infections in 
C57BL/6 versus BALB/c mice, as well as comparisons 
of infections with the two most commonly used lines of 
P. berghei NK65, the Edinburgh line (P. berghei NK65-E) 
and the New York line (P. berghei NK65-NY) in C57BL/6 
mice. Furthermore, induction of MA-ARDS was com-
pared between P. berghei NK65-infected C57BL/6 mice 
and P. berghei ANKA-infected DBA/2 mice. This study 
illustrates that, similar to ECM, both host and parasite 
genetics are important determinants of the induction 
and severity of MA-ARDS and that the lung pathology 
coincides with normocyte invasion. These data yield new 
insights into the pathogenesis and provide information 
for the choice of different mouse-parasite combinations 
to study MA-ARDS.
Methods
Ethical statement
All experiments were approved by the Animal Ethics 
Committee from the KU Leuven (License LA1210186 
Belgium) and by the Animal Experiments Committee 
of the Leiden University Medical Center (DEC 12120). 
The Dutch Experiments on Animal Act is established 
under European guidelines (EU directive no. 86/609/EEC 
regarding the Protection of Animals used for Experimen-
tal and Other Scientific Purposes). All experiments were 
performed in accordance with relevant guidelines and 
regulations.
Parasites and mice
Two different lines of the NK65 strain of P. berghei were 
used.
1) The ‘Edinburgh’ line of the  NK65 strain (P. berghei 
NK65-E). This line is a kind gift of the late Prof. Dr. 
D. Walliker (University of Edinburgh, UK) [18]. 
The genome of a cloned line of this strain (1995cl2; 
RMgm-1115, http://www.pberg hei.eu) has been 
sequenced [31]. This line has been used to generate 
the GFP-luciferase expressing line P. berghei NK65-E 
2168cl2 as previously described [32] (Rmgm-4363; 
http://www.pberg hei.eu).
2) The ‘New York’  line of the NK65 strain (P. berghei 
NK65-NY). This line was a kind gift of Prof. R. 
Ménard (Institut Pasteur, Unité de Biologie et Géné-
tique du Paludisme, Paris, France). The genome of 
a cloned line of P. berghei NK65-NY has also been 
sequenced [31]. This line has been used to gener-
ate a cloned line expressing GFP-luciferase (1556cl1; 
RMgm-4364, http://www.pberg hei.eu) that has been 
used in this study [31, 33].
In addition, the sequenced reference line of P. berghei 
ANKA (cl15cy1) was used [31].
Male and female C57BL/6 mice were obtained from 
Janvier (7–8  weeks old, Le Genest-Saint-Isle, France). 
For the bioluminescence imaging experiments per-
formed at the LUMC, female C57BL/6 (6–7  weeks old) 
from Charles River were used. Mice were infected with 
P. berghei lines NK65-E, NK65-E 2168cl2, NK65-NY or 
P. berghei ANKA by intraperitoneal (IP) injection of  104 
infected RBCs [18, 31, 32, 34].
Mice were kept in a conventional animal house and 
drinking water was supplemented with 4-amino benzoic 
acid (0.375  mg/ml PABA, Sigma-Aldrich, Bornem, Bel-
gium). For the bioluminescence experiments performed 
at LUMC, 4-amino benzoic acid was added to the mouse 
diet. Mice were sacrificed at indicated time points after 
infection by euthanasia with Dolethal (Vétoquinol, Aart-
selaar, Belgium; 200 mg/ml, IP injection of 50 µl).
Determination of parasitaemia and reticulocytosis
A blood smear was taken at indicated time points and 
stained with Giemsa (1/10 dilution, VWR, Heverlee, 
Belgium) to obtain percentages of parasitaemia, reticu-
locytes and infected reticulocytes. Additionally, 1/500 
diluted tail blood was counted using a Bürker chamber 
to obtain RBC concentrations, from which numbers 
of iRBCs, reticulocytes and infected reticulocytes per 
ml were calculated. Images of Giemsa-stained blood 
smears were taken at a magnification of 100 (100×/1.25 
oil objective) with a Leica DM 2000 light microscope 
equipped with a DFC 295 camera (Leica Bond Max, Leica 
Microsystems, Diegem, Belgium).
For determination of parasitaemia by flow cytometry 
[35], tail blood (10 µl) from infected mice was collected 
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in 1  ml of complete culture medium and cells were 
fixed in 1  ml of a 0.25% (v/v) glutaraldehyde solution 
in PBS at 4  °C and kept at 4  °C until analysis. These 
samples were stained with the DNA-specific fluores-
cent dye Hoechst-33258 (2 µmol/l) for 1 h at 37 °C and 
analysed with a a FACScan (LSR II, Becton–Dickinson). 
The fluorescence intensity and size (Forward Scatter; 
FSC; Sideward Scatter, SSC) of 50,000 cells per sample 
were measured and data analysis was performed using 
the FlowJo software (FlowJo, LLC, Ashland, USA).
Quantification of lung pathology
Lung pathology was assessed by measuring the weights 
of unperfused small lungs and the protein and IgM 
concentrations in bronchoalveolar lavage fluid (BALF). 
To obtain BALF, the small lungs were pinched off, 
500  μl of PBS was instilled in the large lungs through 
the trachea with a catheter and withdrawn after 30  s. 
This was repeated and both lavages were pooled. The 
BALF was centrifuged (10 min at 335 g, 4 °C), the pro-
tein concentration of the supernatant was determined 
by Bradford assay (Bio-Rad, Hercules, CA, USA) and 
IgM concentrations were determined by ELISA (Jack-
son Immunoresearch, Newmarket, UK). Cell pellets 
were resuspended and leukocytes and erythrocytes 
were counted in a Bürker chamber. The RBCs were 
lysed by  NH4Cl treatment (0.83%  NH4Cl, 10 mM Tris/
HCl, pH 7.2) and the leukocytes were further mounted 
onto cytospin slides (Thermo Shandon, Cheshire, UK), 
which were prepared and stained with Hemacolor 
(Merck, Darmstadt, Germany). The percentages of lym-
phocytes, monocytes/macrophages, and neutrophils 
were determined by microscopy analysis of the cyto-
spin slides.
Determination of parasite accumulation in the lungs 
by luminescence imaging
Mice were IP injected with  104 of the parasite lines 
P. berghei NK65-NY 1556cl1 and P. berghei NK65-E 
2168cl2. Both lines express the fusion protein GFP-
luciferase. In vivo imaging of luminescence was used to 
determine the relative parasite accumulation in the lungs 
[33]. Mice were anesthetized and received d-luciferin 
(100 mg/kg, Caliper Life Sciences) subcutanously in the 
scruff, 2 min before full body imaging. Luciferase activity 
was determined using an IVIS Lumina II in  vivo Imag-
ing System (Perkin Elmer Life Sciences, Waltham, USA). 
Quantitative analysis of bioluminescence of whole bod-
ies was performed by measuring the luminescence signal 
intensity using the region of interest (lungs) settings of 
the Living Image 4.4 software.
Determination of parasite accumulation in the lungs 
by qRT‑PCR
After mechanical homogenization of the left lungs, total 
RNA was extracted (RNeasy mini kit, Qiagen, Hilden, 
Germany) and quantified (Nanodrop, Thermo Fischer, 
Aalst, Belgium). cDNA was synthesized (High capac-
ity cDNA reverse transcription kit, Thermo Fischer), 
and quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) for mouse and parasite 18S was per-
formed on 0.5 and 0.25 ng cDNA. The parasite 18S was 
determined with the following primer and probe sets, 
synthesized by Integrated DNA Technologies (IDT, Leu-
ven, Belgium): TAA CAT GGC TTT GAC GGG TAA (for-
ward primer), TGC TGC CTT CCT TAG ATG TG (reverse 
primer) and TCC GGA GAG GGA GCC TGA GAA ATA 
(probe). P. berghei 18S data was normalized to the cor-
responding expression of the murine 18S RNA.
Scoring of disease progression
As described previously [36], body weight, parasitaemia, 
and clinical parameters including spontaneous activ-
ity (SA), limb grasping (LG), body tone (BT), trunk curl 
(TC), pilo-erection (PE), shivering (Sh), abnormal breath-
ing (AB), dehydration (D), incontinence (I) and paralysis 
(P) were evaluated daily to calculate a clinical score of 
disease severity. A disease score was given of 0 (absent) 
or 1 (present) for TC, PE, Sh and AB and 0 (normal), 1 
(intermediate) or 2 (most serious) for the other parame-
ters. The total clinical score was calculated by the follow-
ing formula: SA + LG + BT + TC + PE + Sh + AB + 3 * (D 
+ I + P). Mice were euthanized when humane endpoints 
were reached (clinical score of 15 or more) or at the indi-
cated time points.
Determination of RBC turnover
Mice were injected intravenously with 100 µl Sulfo-NHS-
biotin (EZ-link sulfo-NHS-LC-biotin, Thermo Scien-
tific, Rockford, US) in PBS at 10 mg/ml, which results in 
rapid and efficient biotinylation of RBCs. At several times 
thereafter (at least 4  h), tail blood was collected, RBC 
were counted in a haemocytometer and subsequently 
labelled with streptavidin-APC (eBiosciences, CA, USA) 
and analysed by flow cytometry (FACSCalibur, Beckton 
Dickinson, Erembodegem, Belgium). Non-biotinylated 
blood was used as a negative control.
Statistical analysis
The Mann–Whitney U test was used to determine the 
statistical significance between two groups. Statisti-
cal analysis was done using the GraphPad Prism 7 soft-
ware (GraphPad software, San Diego, USA). p-values 
smaller than 0.05 were considered statistically significant. 
Page 5 of 17Vandermosten et al. Malar J  (2018) 17:102 
p-values were defined as follows: *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. Occasional mice in which 
the parasite did not develop well (< 1% parasitaemia on 
day 9–10 post-infection (PI) for P. berghei NK65-E) were 
excluded. Unless otherwise specified, bars and curves 
represent the average with standard error of the mean. 
Asterisks without horizontal lines represent significant 
differences compared to the uninfected control group. 
Horizontal lines with asterisks on top indicate significant 
differences between groups.
Results
Brief history of used parasite lines and clones
Plasmodium berghei NK65 was originally isolated from 
an Anopheles dureni millecampsi mosquito in 1964 [37]. 
Subsequently, this parasite was sent to several laborato-
ries over the world. Previously, it was shown that para-
sites from the ‘Edinburgh’ line of P. berghei NK65 cause 
MA-ARDS in C57BL/6 mice [17, 18, 32]. However, it was 
subsequently noticed that, parasites of the ‘New York’ 
line of P. berghei NK65 differed from P. berghei NK65-E 
in infection characteristics, such as development of para-
sitemia. The genomes of cloned lines of both P. berghei 
NK65-E and P. berghei NK65-NY have been sequenced 
[31]. Several transgenic clones of P. berghei NK65-E 
were generated, including a cloned line which expresses 
GFP-luciferase under the control of the schizont-specific 
ama-1 promoter [32], which is designated as P. berghei 
NK65-E 2168cl2.
A comparable cloned line was generated using para-
sites of P. berghei NK65-NY. As in P. berghei NK65-E 
2168cl2, a gfp-luciferase fusion gene under control of the 
ama-1 promoter has been introduced into the silent c/d 
type ssu-rRNA locus of parasites of P. berghei NK65-NY 
[32]. This cloned line is designated as P. berghei NK65-
NY 1556cl1.
Epiphanio et  al. [23] described that DBA/2 mice 
infected with P. berghei ANKA results in MA-ALI in 
a proportion of the mice. Therefore, parasite growth 
and lung pathology levels were analysed and compared 
in C57BL/6 mice infected with P. berghei NK65-E or 
P. berghei NK65-NY and in DBA/2 mice infected with 
the sequence reference cloned line cl15cy1 of P. berghei 
ANKA [31].
Comparison of lung pathology between C57BL/6 mice 
infected with P. berghei NK65‑E or P. berghei NK65‑NY 
and DBA/2 mice infected with P. berghei ANKA
The peripheral parasitaemia increased early in P. berghei 
NK65-E-infected C57BL/6 mice and led to morbid-
ity and mortality around day 9 PI. P. berghei NK65-NY-
infected C57BL/6 mice developed detectable, but low 
parasitaemia between 7 and 11  days PI and thereafter, 
parasitaemia increased rapidly before termination of the 
experiment. More severe lung pathology was observed 
in C57BL/6 mice infected with P. berghei NK65-E com-
pared to P. berghei NK65-NY (Fig.  1). P. berghei NK65-
E induced a full spectrum of pathology including an 
increase in lung weight, extensive alveolar oedema (as 
indicated by protein and IgM levels in the BALF), alveo-
lar infiltration of immune cells and a high clinical score 
within 9  days PI, whilst mice infected with P. berghei 
NK65-NY developed a less pronounced lung pathology 
with minor increases of numbers of lymphocytes, mac-
rophages and erythrocytes in the BALF at day 9 PI and 
subtle alveolar oedema. However, the changes in these 
parameters were considerably lower compared to mice 
infected with P. berghei NK65-E and did not result in a 
clearly increased clinical scores (Figs.  1, 2). Erythrocyte 
numbers in BALF of P. berghei NK65-E-infected C57BL/6 
mice were greatly increased, indicating the occurrence 
of microhaemorrhages as previously described [18]. In 
P. berghei ANKA-infected DBA/2 mice, parasitaemia 
increased gradually from day 5 PI onwards until hyper-
parasitaemia at 3  weeks PI. An increase in lung weight 
and a transient and mild alveolar oedema was detected 
with no significant evidence of microhaemorrhages and 
a sparse infiltration of immune cells in the BALF (Figs. 1, 
2). Only 10% of the P. berghei ANKA-infected DBA/2 
mice died around 10 days PI, whereas in the other 90%, 
the alveolar oedema decreased after day 9 PI and mice 
recovered until they reached humane endpoints with 
hyperparasitaemia and anaemia after 19 days PI. A cor-
respondingly transient and mild clinical score was noted 
around day 9 PI, which again increased at the end of the 
experiment. 
Altogether, these results show that P. berghei NK65-E-
infected C57BL/6 mice developed the most severe lung 
pathology, consistent with MA-ARDS. P. berghei ANKA-
infected DBA/2 mice developed a less severe and tran-
sient form of lung pathology, and infection with P. berghei 
NK65-NY did not lead to overt lung pathology.
The development of lung pathology is mouse 
strain‑dependent
To investigate the influence of the mouse strain on exper-
imental MA-ARDS, BALB/c mice were infected with P. 
berghei NK65-E and compared to P. berghei NK65-E-
infected C57BL/6 mice (Fig. 3). While P. berghei NK65-E-
infected C57BL/6 mice developed MA-ARDS around day 
9 PI at a parasitaemia above 10%, infected BALB/c mice 
developed a gradually increasing parasitaemia from day 
6 PI onwards until hyperparasitaemia at 15 days PI. The 
lung weight increased significantly upon infection in both 
parasite-mouse combinations, but was most pronounced 
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Fig. 1 P. berghei NK65‑E‑infected C57BL/6 mice developed more severe lung pathology compared with P. berghei ANKA‑infected DBA/2 mice 
and P. berghei NK65‑NY‑infected C57BL/6 mice. C57BL/6 mice were infected with P. berghei NK65‑E or P. berghei NK65‑NY and DBA/2 mice were 
infected with P. berghei ANKA. a Peripheral parasitaemia levels were determined through blood smears at the indicated time points (n = 7–32 
per group). Mice were sacrificed at the indicated times and lung weight b, protein content c and IgM concentration d in BALF were measured 
(control: n = 4–10 per group, infected: n = 7–23 per group). e Clinical score was monitored throughout the course of infection (control: n = 4–8 per 
group, infected: 8–20 per group). Asterisks on top of the bars indicate significant differences compared to the uninfected control group. Horizontal 
lines with asterisks on top indicate significant differences between groups and horizontal lines with n.s. on top indicate no significant differences 
between groups 
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in P. berghei NK65-E-infected C57BL/6 mice. This was 
paralleled by an increase in alveolar oedema, which was 
only minor in BALB/c infected animals.
Infection of BALB/c mice with P. berghei NK65-E 
resulted in infiltration of macrophages and lymphocytes, 
but not neutrophils, into the lung (Fig. 3). However, the 
numbers of infiltrating macrophages and lymphocytes 
were lower compared to P. berghei NK65-E-infected 
C57BL/6 mice. Taken together, these data indicate that P. 
berghei NK65-E induces pronounced MA-ARDS, only in 
C57BL/6 mice and not in BALB/c mice. Additionally, P. 
berghei ANKA does not induce extensive lung pathology 
Fig. 2 P. berghei NK65‑E‑infected C57BL/6 mice develop the highest alveolar leukocyte infiltration and haemorrhages. C57BL/6 mice were infected 
with P. berghei NK65‑E or P. berghei NK65‑NY and DBA/2 mice were infected with P. berghei ANKA. Mice were sacrificed at the indicated time points. 
a Macrophages, b lymphocytes and c neutrophils were differentially counted in cytospins of BALF (control: n = 4–10 per group, infected: n = 7–23 
per group). d Erythrocytes were counted in BALF (control: n = 4–8 per group, infected: n = 6–18 per group). Asterisks on top of the bars indicate 
significant differences compared to the uninfected control group. Horizontal lines with n.s. on top indicate no significant differences between 
groups
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in BALB/c (Fig. 3), in contrast to its ability to induce lung 
oedema in DBA/2 mice (Fig. 1) or in C57BL/6 mice [15, 
23].
MA‑ARDS pathogenesis is independent of sex in P. berghei 
NK65‑infected C57BL/6 mice
Given previous studies that showed that male mice are 
less susceptible to some aspects of malaria pathogenesis 
than females [38–41], the course of P. berghei NK65-E 
infections and lung pathology between male and female 
C57BL/6 mice were compared (Fig.  4). Besides a minor 
difference on day 6 PI, the parasitaemia was not different 
between infected male and female C57BL/6 mice. Both 
male and female C57BL/6 mice developed lung pathology 
at 9–10 days PI in the P. berghei NK65-E model without 
significant differences (Fig. 4).
The tissue tropism of P. berghei NK65‑E and P. berghei 
NK65‑NY are similar, but the kinetics of accumulation 
in the lungs differ
Since peripheral parasitaemia in malaria excludes the 
iRBCs that are sequestering or accumulating  in the 
organs, the parasite accumulation in the lungs of mice 
infected with P. berghei NK65-NY and P. berghei NK65-
E was analysed. C57BL/6 mice were infected with GFP-
luciferase expressing lines of these parasites (i.e. P. 
berghei NK65-NY and P. berghei NK65-E 2168cl2). These 
parasites express the fusion protein GFP-luciferase under 
control of a schizont-specific promotor, which allows 
visualization and quantification of schizonts through its 
luciferase activity by in  vivo whole body imaging [31, 
32]. A gradual increase in schizont accumulation until 
day 8 PI was seen in the lungs and umbilical fat tissue of 
P. berghei NK65-E 2168cl2 infected mice which develop 
MA-ARDS on day 7–8 PI (Fig.  5) [32]. In P. berghei 
NK65-NY-infected mice, which did not develop MA-
ARDS, schizont accumulation increased gradually in the 
lungs and umbilical fat tissue at a reduced rate till day 7 
PI, followed by a small drop and again a gradual increase 
until day 19 PI. Furthermore, parasites were quantified by 
qRT-PCR of parasite 18S in perfused lungs of P. berghei 
NK65-E and P. berghei  NK65-NY-infected mice, as an 
accurate marker for parasite accumulation (Fig.  5c). On 
day 9 PI, parasite accumulation in the perfused lungs of 
P. berghei NK65-NY infected mice was significantly lower 
compared to P. berghei NK65-E infected mice, which con-
firmed the bioluminescence data. Moreover, the accumu-
lation of P. berghei NK65-NY at day 22 PI was higher than 
with P. berghei NK65-E at day 9 PI, in accordance to the 
higher parasitemia. These data suggested that the distri-
bution of P. berghei NK65-E and P. berghei NK65-NY par-
asites over different organs in the body are similar, and 
hence suggest that these parasite lines do not show major 
differences in their tissue tropism. However, the kinetics 
of the parasite accumulation is parasite-dependent and 
parallels the peripheral parasitaemia. Based on the lumi-
nescence data, the level of schizont accumulation in the 
lungs in P. berghei NK65-NY infected mice on day 19 PI 
was similar to that in P. berghei NK65-E 2168cl2 infected 
mice on day 7–8 PI (Fig. 5). However, this did not result 
in MA-ARDS in the P. berghei NK65-NY-infected mice, 
in contrast with the pronounced lung pathology in the P. 
berghei NK65-E-infected mice (Fig. 1). This suggests that 
pulmonary parasite accumulation alone is not enough to 
explain the pathology and that additional factors, possi-
bly related to the capacity of infecting normocytes, con-
tribute to the pathogenesis.
Dynamics of reticulocytosis and RBC turnover in P. berghei 
NK65‑E‑ and P. berghei NK65‑NY‑infected C57BL/6 mice 
and in P. berghei ANKA‑infected DBA/2 mice
Upon infection of C57BL/6 mice, P. berghei NK65-E 
and P. berghei NK65-NY displayed a different ability to 
invade RBCs of different ages. Initially, P. berghei NK65-E 
appeared to prefer invading reticulocytes. After the first 
week of infection, all available reticulocytes had been 
depleted and P. berghei NK65-E grew exponentially from 
7 days PI onwards (Fig. 1). This coincided with a switch 
whereby parasites of the P. berghei NK65-E strain were 
found to invade mainly normocytes (Fig. 6). These obser-
vations indicate that P. berghei NK65-E has a predilec-
tion for invading reticulocytes, but that it can also infect 
normocytes in the absence of sufficient reticulocytes. 
This switch from reticulocyte to normocyte invasion 
coincided with the increase of the clinical score (Fig. 1). 
Mild anaemia developed shortly before P. berghei NK65-
E-infected C57BL/6 mice died from MA-ARDS (Fig. 6).
Similar to P. berghei NK65 infections, P. berghei 
ANKA infection in DBA/2 mice demonstrated a rela-
tive preference for reticulocytes. Parasitaemia rose 
(See figure on next page.)
Fig. 3 P. berghei NK65‑E induces pronounced MA‑ARDS in C57BL/6 mice but not in BALB/c mice. C57BL/6 mice were infected with P. berghei 
NK65‑E, BALB/c mice were infected with P. berghei NK65‑E or P. berghei ANKA. a Peripheral parasitaemia was determined through blood smears 
at the indicated time points (n = 3–21 per group). b Lung weight and c protein content in BALF were measured when mice were sacrificed at 
the indicated time points (control: n = 4–6 per group, infected: n = 5–12 per group). d Macrophages, e lymphocytes and f neutrophils were 
differentially counted in cytospins of BALF (control: n = 4–6 per group, infected: n = 5–12 per group). Asterisks on top of the bars indicate significant 
differences compared to the uninfected control group. Horizontal lines with n.s. on top indicate no significant differences between groups
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above 0.1% at 5  days PI and continued to increase 
steadily until around 30% at 19 days PI (Fig. 1). Reticu-
locyte numbers were relatively low in the control mice 
and in infected mice during the first phase of infection 
(up to day 9 PI) (Fig.  6). During this period, around 
80% of the reticulocytes were infected. However, since 
parasite numbers were higher than reticulocyte num-
bers, between 75 and 100% of the parasites resided in 
normocytes (Fig.  6). RBC numbers decreased during 
the course of infection with a 62% reduction on day 19 
compared to day 5 PI (Fig. 6). After 9 days PI, reticulo-
cyte numbers increased, presumably as a consequence 
of the erythropoietic response to anaemia, and the par-
asite concomitantly infected more reticulocytes than 
normocytes (Fig.  6). This reflects the preference of P. 
berghei ANKA for reticulocytes, although it can infect 
normocytes when only low numbers of reticulocytes 
are available. Interestingly, the switch from normocyte 
to reticulocyte corresponded to a striking decrease in 
clinical score (Fig. 1), suggesting that the parasite is less 
pathogenic when it infects reticulocytes.
In P. berghei NK65-NY-infected C57BL/6 mice, para-
sitaemia remained below 3% until 14 days PI (Fig. 1). At 
7  days PI, parasites were detected in both reticulocytes 
and normocytes. Later during the infection, the number 
of reticulocytes started to increase and from 14  day PI 
onwards, high reticulocyte numbers were observed. This 
was concomitant with a high parasitaemia, and parasites 
were detected almost exclusively in reticulocytes (Fig. 6). 
Anaemia also continued to aggravate with a 50% reduc-
tion of RBC numbers on day 20 compared to day 7 PI 
(Fig.  6). Of the reticulocytes, between 40 and 80% was 
infected throughout the course of infection (Fig. 6). These 
data suggest that NK65-NY has a strong predilection for 
reticulocytes and that it cannot develop increased para-
sitaemia in normocytes, in contrast to P. berghei NK65-E 
and P. berghei ANKA.
To further demonstrate the reticulocyte-predilection 
of P. berghei NK65-NY during the complete course of 
infection in C57BL/6 mice, the RBC dynamics that result 
in anaemia were investigated. The RBC turnover was 
determined by in  vivo biotin-labelling of RBCs 7  days 
PI. By quantifying the percentage of biotinylated versus 
Fig. 4 P. berghei NK65‑E induces MA‑ARDS in C57BL/6 mice independently of the sex. Male and female C57BL/6 mice were infected with P. berghei 
NK65‑E (PbNK65‑E). a Peripheral parasitemia was determined through blood smears at indicated time points (n = 10–33 per group). b Upon 
dissection at 9–10 days PI, alveolar oedema was measured by protein determination (control: n = 15–17 per group, infected: n = 15–24 per group). 
c The lung weight was determined (control: n = 14–15 per group, infected: n = 18–30 per group). Asterisks on top of the bars indicate significant 
differences compared to the uninfected control group. Horizontal lines with n.s. on top indicate no significant differences between groups
(See figure on next page.)
Fig. 5 Tissue tropism of the P. berghei NK65‑NY and P. berghei NK65‑E parasite. C57BL/6 mice were infected with P. berghei NK65‑NY (green, 
PbNK65‑NY) or P. berghei NK65‑E 2168cl2 (red, PbNK65‑E). a Peripheral parasitemia was determined through flow cytometry at indicated time 
points. b The accumulation of P. berghei NK65 schizonts in lungs was measured and visualized through the bioluminescent features of the GFP‑luc 
transfected parasites at the indicated time points and expressed as relative light units (RLU) (n = 8 per group). Asterisks indicate significant 
differences between groups. c C57BL/6 mice were infected with P. berghei NK65‑NY or P. berghei NK65‑E, and parasite loads in perfused large lungs 
were determined by quantifying parasite 18S RNA transcripts by RT‑qPCR (n = 8–11 per group). Asterisks on top of the bars indicate significant 
differences compared to the uninfected control group. Horizontal lines with asterisks on top indicate significant differences between groups. d 
Whole‑body bioluminescence images of representative infected mice are shown
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non-biotinylated cells using flow cytometry, it is pos-
sible to visualize both the clearance of RBCs from the 
circulation and the generation of new RBCs from the 
bone marrow (Fig.  7). In the period between day 7 PI 
and the end of the experiment (day 20 PI), the labelled 
RBCs (bioRBCs) disappeared at a similar rate in unin-
fected controls and infected mice, despite the relatively 
high parasitaemia after day 11 PI. This demonstrated that 
the turnover of the bioRBCs, which corresponded to the 
RBCs already present at day 7 PI and consisting of mainly 
normocytes, did not increase during infection. This sug-
gests that few or no labelled normocytes were destroyed 
by P. berghei NK65-NY (Fig. 7) and supports the idea that 
this parasite has a pronounced predilection for reticulo-
cytes over normocytes.
In contrast with the comparable turnover of bioRBCs, 
the number of unlabelled RBCs, which correspond to 
RBCs newly formed after the biotinylation on day 7 PI, 
was lower in the infected mice compared to the unin-
fected controls (Fig.  7). Calculation of the number of 
reticulocytes based on the microscopical analysis of the 
blood smears revealed that in uninfected mice, only a 
small proportion of the newly formed RBCs were retic-
ulocytes, which is in agreement with the rapid matura-
tion of reticulocytes into normocytes (typically less than 
1  day). However, in the infected mice, the unlabelled 
RBCs consisted mainly of reticulocytes instead of normo-
cytes. This suggests that the reticulocytes in the infected 
mice are immediately infected and destroyed before 
they can mature into (unlabelled) normocytes (Fig.  7). 
This explanation is plausible given that one erythrocytic 
cycle of the parasite, from invasion to rupture lasts 24 h 
and given the high percentage of infected reticulocytes 
observed. These data also indicate that, in this model, 
destruction of reticulocytes by the parasite contributes to 
the lack of replenishment of new normocytes, which is a 
main cause of anaemia. Interestingly, the newly formed 
non-biotinylated RBCs from infected mice are larger in 
size from day 14 PI onwards, compared to reticulocytes 
from uninfected control mice, as detected both by light 
microscopy analysis and by analysis of forward scatter 
by flow cytometry. This suggests that reticulocytes are 
released in a more immature stage from the bone marrow 
or spleen in the infected mice from day 14 PI onwards 
[42], in line with a strong stimulation of erythropoiesis by 
the anaemia.
Discussion
The development of MA-ARDS in mice appears highly 
dependent on both mouse and parasite strains. In the 
current study, it is shown that MA-ARDS develops with 
P. berghei NK65-E, whereas P. berghei NK65-NY causes 
only minor pulmonary oedema. Also, the genetic back-
ground of the host is crucial, as MA-ARDS develops in 
C57BL/6 mice but not in BALB/c mice. Furthermore, 
DBA/2 mice infected with P. berghei ANKA also develop 
lung pathology, but clearly to a lower degree as indicated 
by the lower alveolar oedema. The latter parasite-mouse 
combination results in lethality in only a fraction of the 
DBA/2 mice, whereas the other mice survive the tran-
sient phase of the lung pathology and develop hyperpara-
sitaemia and anaemia later on.
The differential susceptibility of mouse strains to spe-
cific malaria complications is a common observation. 
It is well-known that P. berghei ANKA-induced ECM 
develops quickly in C57BL/6 mice and CBA/J mice, 
whereas BALB/c and DBA/2 mice are resistant to this 
condition [29, 43]. Infection of BALB/c with Plasmo-
dium yoelii XL is lethal, but the same parasite in DBA/2 
mice is not lethal, causing a transient parasitaemia [44]. 
Furthermore, infection of C57BL/6 or BALB/c mice 
with P. chabaudi AS results in a transient parasitaemia 
wave together with limited liver pathology; however, P. 
chabaudi AS causes lethal anaemia in A/J mice [45–47]. 
Several genetic factors play a role in the susceptibility 
of the host to the parasite. In particular, a genetic back-
ground biased to more severe Th1 immune responses 
may be more prone to the development of Th1-mediated 
pathology. This is illustrated by the increased  CD8+ T 
cell activation and CXCR3 expression in C57BL/6 mice 
versus BALB/c mice, resulting in ECM in the C57BL/6 
mice only [43]. However, the timing and potency of the 
Th1 response can have differential effects depending on 
the infecting parasite. Whilst DBA/2 mice are resistant 
to the development of P. berghei ANKA-induced cerebral 
pathology, a more potent Th1 response mounted to P. 
yoelii results in a more efficient parasite control in DBA/2 
mice compared to BALB/c mice [44].
Fig. 6 P. berghei NK65‑E shifts from reticulocytes to normocytes and P. berghei ANKA and P. berghei NK65‑NY from normocytes to reticulocytes. 
C57BL/6 mice were infected with P. berghei NK65‑E (PbNK65‑E) or P. berghei NK65‑NY (PbNK65‑NY), and DBA/2 mice were infected with P. berghei 
ANKA (PbA). a Number of RBCs and b reticulocytes per µl blood, c percentages of infected reticulocytes and d percentages of parasites in 
reticulocytes and normocytes were determined at the indicated time points (control: n = 4 per group, infected: n = 8–12 per group). e Pictures from 
the Giemsa‑stained smears are shown to illustrate the preference of the parasites for normocytes or reticulocytes. Arrows indicate infected RBCs and 
the black line represents 20 µm. Asterisks indicate significant differences between groups
(See figure on next page.)
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Differences between parasite strains and laboratory 
lines are crucial in determining the severity of malarial 
disease. Previous reports have highlighted differences 
in virulence between clones of P. berghei ANKA for the 
induction of ECM [29]. Also, several cloned lines of P. 
chabaudi have been shown to induce different levels of 
anaemia and weight loss across several different murine 
backgrounds [48, 49]. Of relevance to this study, P. 
chabaudi CB is more virulent than P. chabaudi AS and 
induces pulmonary pathology [26]. Importantly, mul-
tiple passaging of parasites may affect their virulence, 
as was shown for P. chabaudi AS [50]. Prominent dif-
ferences especially occur between parasites that were 
recently passaged through mosquitos and parasites that 
were passaged several times by blood transfer. The lat-
ter procedure enhances the virulence, and this appears 
to be related to a more restricted pattern of expression 
of the pir multigene family [51].
Here, it is shown that two laboratory lines of P. berghei 
NK65 differed strikingly in terms of MA-ARDS induc-
tion. These lines presumably originate from one strain 
since it was isolated from a single infected mosquito 
[37]. Most likely, the passaging of parasites of this strain 
in different laboratories has resulted in the pronounced 
phenotypic differences between P. berghei NK65-E and 
P. berghei NK65-NY. The genetic diversity between these 
two lines is limited, as determined by genome sequencing 
recently [31]. However, these data suggested a more pro-
nounced reticulocyte predilection of P. berghei NK65-NY 
compared to P. berghei NK65-E. Some P. berghei NK65-
NY parasites, including ring stages, were observed in 
normocytes at 7 days PI, suggesting that P. berghei NK65-
NY has the ability to invade normocytes. However, the 
Fig. 7 RBC turnover indicates predilection of P. berghei NK65‑NY parasites for reticulocytes in C57BL/6 mice. C57BL/6 mice were infected with P. 
berghei NK65‑NY (PbNK65‑NY). RBCs were in vivo biotin‑labeled 7 days PI and the percentage of biotinylated (BioRBCs) versus non‑biotinylated cells 
was quantified by flow cytometry (control: n = 7 per group, infected: n = 8 per group). a Number of RBCs per µl of blood. The non‑biotinylated RBCs 
were subdivided into reticulocytes and normocytes, according to microscopy countings of the Giemsa‑stained blood smears. b Representative 
FACS plots of RBCs of control mice (upper row) and infected mice (lower row), showing the percentage of BioRBCs and the forward scatter (FSC)
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replication in normocytes appeared inefficient as para-
sitaemias above 3% were only observed when sufficient 
numbers of reticulocytes were available. Furthermore, 
in vivo analysis of the RBC turn-over confirmed that only 
very few or no normocytes were destroyed by P. berghei 
NK65-NY. This reticulocyte predilection was associated 
with the absence of lung pathology. The switch from 
infection of reticulocytes to normocytes is important for 
rapid and early increases in P. berghei NK65-E parasitae-
mia, which coincides with the occurrence of pulmonary 
pathology.
P. berghei is known to have preference for invading 
reticulocytes versus normocytes [52]. Interestingly, Hopp 
et al. [53] described recently that berghepain-1 is a cru-
cial protease for the infectivity of normocytes, as berghe-
pain-1 knockout  of P. berghei ANKA was completely 
reticulocyte-restricted. The growth of this parasite was 
limited by the availability of reticulocytes, similar to the 
here described findings with P. berghei NK65-NY, and 
could even be enhanced by treating the mice with phe-
nylhydrazine, which results in RBC lysis and secondary 
reticulocytosis. Similarly, chloroquine-resistant P. berghei 
ANKA is also reticulocyte-restricted and produces 
less haemozoin, explaining the decreased sensitivity to 
chloroquine [54]. Plasmepsin-4/berghepain-2 double 
knockout parasites produce almost no haemozoin, are 
chloroquine-insensitive and are reticulocyte-restricted. 
They display a severe delayed growth phenotype and 
diminished ECM pathogenicity [55]. Furthermore, 
induction of reticulocytosis by administration of erythro-
poietin is also protective in the P. berghei ANKA model 
of cerebral malaria, although direct anti-inflammatory 
and neuroprotective actions of erythropoietin may be 
involved as well [56–58]. Lastly, the importance of being 
a generalist in RBC invasion can be highlighted by P. 
yoelii, as the non-lethality in the reticulocyte-invading 
XNL strain is contrasted with the lethal generalist XL 
strain [59]. Here, it was found that MA-ARDS occurs 
in P. berghei NK65-E infected C57BL/6 mice, when the 
parasite switches from invading mainly reticulocytes to 
invading mainly normocytes, and that the lung pathology 
in P. berghei ANKA-infected DBA/2 mice resolves when 
the parasite switches from invading normocytes to invad-
ing reticulocytes. The reasons why infected reticulocytes 
appear less pathogenic than normocyte invasion are 
currently unknown and may include a lower content of 
pathogenic factors in infected reticulocytes compared to 
infected normocytes, or the induction of a disease-limit-
ing response by infected reticulocytes but not by infected 
normocytes.
Altogether, these data suggest that distinct lines of the 
P. berghei NK65 strain exist with completely different 
characteristics regarding the MA-ARDS pathology, and 
that the P. berghei parasite is more pathogenic when it 
resides in normocytes compared to reticulocytes, even 
at similar parasitemia levels, iRBC load and distribution 
in different organs. This association between reticulo-
cyte invasion and absence of lung pathology is in line 
with human infections, as MA-ARDS is relatively less 
lethal upon infection with the reticulocyte-restricted P. 
vivax than with P. falciparum [9]. Future investigations 
are needed to clarify the mechanisms that underly the 
differences in MA-ARDS induced by different parasite 
lines. The data in this study emphasize the importance 
of choosing the correct mouse-parasite combinations 
to study mechanisms underlying MA-ARDS.
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